Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aberrations in the rearranged during transfection (RET) oncogene are implicated in various malignancies, particularly lung and thyroid cancers.
• Current targeted therapies using multi-kinase inhibitors (MKIs) for RET-altered cancers show limited efficacy and significant off-target toxicity.
• The U.S. Food and Drug Administration (FDA) approved a novel, specific RET inhibitor in May 2020.

Purpose of the Study:

• To review the mechanism of action of selpercatinib, a specific RET inhibitor.
• To summarize the pharmaceutical properties and clinical data of selpercatinib.
• To provide perspectives on the clinical application of selpercatinib in RET-altered cancers.

Main Methods:

• Literature review of preclinical and clinical studies on selpercatinib.
• Analysis of mechanism of action, pharmacokinetics, and pharmacodynamics.
• Synthesis of clinical trial data regarding efficacy and safety.

Main Results:

• Selpercatinib demonstrates high selectivity for RET alterations, including fusions and mutations.
• Clinical trials show significant objective response rates and durable responses in patients with RET-altered lung and thyroid cancers.
• Improved safety profile compared to traditional multi-kinase inhibitors with reduced off-target effects.

Conclusions:

• Selpercatinib represents a significant advancement in the targeted therapy of RET-altered lung and thyroid cancers.
• Its specific mechanism of action and favorable clinical data support its role as a first-line treatment option.
• Further research may explore its efficacy in other RET-driven malignancies and combination therapies.